Allergan and Editas Medicine have confirmed a research and development alliance under which Allergan will have exclusive access to and the right to license up to five Edits genome-editing eye disease therapies. The treatment involves CRISPR technology which edits genomes to replace or remove diseased cells. This technology is the latest innovation in eye disease treatment. The deal comes after Allergan’s unveiling of their new program, “See America,” last month which aims to educate about eye diseases. Read the full press release here.